|
|
Newsletter Month
Wed, 01/27/2010 - 5:34pm — mcormican
<!--[if gte mso 9]>
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
MicrosoftInternetExplorer4
<![endif]--><!--[if gte mso 9]>
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
UnhideWhenUsed="false" QFormat="true" Name="Normal" />
UnhideWhenUsed="false" QFormat="true" Name="heading 1" />
UnhideWhenUsed="false" QFormat="true" Name="Title" />
UnhideWhenUsed="false" QFormat="true" Name="Subtitle" />
UnhideWhenUsed="false" QFormat="true" Name="Strong" />
UnhideWhenUsed="false" QFormat="true" Name="Emphasis" />
UnhideWhenUsed="false" Name="Table Grid" />
UnhideWhenUsed="false" QFormat="true" Name="No Spacing" />
UnhideWhenUsed="false" Name="Light Shading" />
UnhideWhenUsed="false" Name="Light List" />
UnhideWhenUsed="false" Name="Light Grid" />
UnhideWhenUsed="false" Name="Medium Shading 1" />
UnhideWhenUsed="false" Name="Medium Shading 2" />
UnhideWhenUsed="false" Name="Medium List 1" />
UnhideWhenUsed="false" Name="Medium List 2" />
UnhideWhenUsed="false" Name="Medium Grid 1" />
UnhideWhenUsed="false" Name="Medium Grid 2" />
UnhideWhenUsed="false" Name="Medium Grid 3" />
UnhideWhenUsed="false" Name="Dark List" />
UnhideWhenUsed="false" Name="Colorful Shading" />
UnhideWhenUsed="false" Name="Colorful List" />
UnhideWhenUsed="false" Name="Colorful Grid" />
UnhideWhenUsed="false" Name="Light Shading Accent 1" />
UnhideWhenUsed="false" Name="Light List Accent 1" />
UnhideWhenUsed="false" Name="Light Grid Accent 1" />
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1" />
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1" />
UnhideWhenUsed="false" Name="Medium List 1 Accent 1" />
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph" />
UnhideWhenUsed="false" QFormat="true" Name="Quote" />
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote" />
UnhideWhenUsed="false" Name="Medium List 2 Accent 1" />
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1" />
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1" />
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1" />
UnhideWhenUsed="false" Name="Dark List Accent 1" />
UnhideWhenUsed="false" Name="Colorful Shading Accent 1" />
UnhideWhenUsed="false" Name="Colorful List Accent 1" />
UnhideWhenUsed="false" Name="Colorful Grid Accent 1" />
UnhideWhenUsed="false" Name="Light Shading Accent 2" />
UnhideWhenUsed="false" Name="Light List Accent 2" />
UnhideWhenUsed="false" Name="Light Grid Accent 2" />
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2" />
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2" />
UnhideWhenUsed="false" Name="Medium List 1 Accent 2" />
UnhideWhenUsed="false" Name="Medium List 2 Accent 2" />
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2" />
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2" />
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2" />
UnhideWhenUsed="false" Name="Dark List Accent 2" />
UnhideWhenUsed="false" Name="Colorful Shading Accent 2" />
UnhideWhenUsed="false" Name="Colorful List Accent 2" />
UnhideWhenUsed="false" Name="Colorful Grid Accent 2" />
UnhideWhenUsed="false" Name="Light Shading Accent 3" />
UnhideWhenUsed="false" Name="Light List Accent 3" />
UnhideWhenUsed="false" Name="Light Grid Accent 3" />
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3" />
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3" />
UnhideWhenUsed="false" Name="Medium List 1 Accent 3" />
UnhideWhenUsed="false" Name="Medium List 2 Accent 3" />
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3" />
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3" />
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3" />
UnhideWhenUsed="false" Name="Dark List Accent 3" />
UnhideWhenUsed="false" Name="Colorful Shading Accent 3" />
UnhideWhenUsed="false" Name="Colorful List Accent 3" />
UnhideWhenUsed="false" Name="Colorful Grid Accent 3" />
UnhideWhenUsed="false" Name="Light Shading Accent 4" />
UnhideWhenUsed="false" Name="Light List Accent 4" />
UnhideWhenUsed="false" Name="Light Grid Accent 4" />
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4" />
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4" />
UnhideWhenUsed="false" Name="Medium List 1 Accent 4" />
UnhideWhenUsed="false" Name="Medium List 2 Accent 4" />
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4" />
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4" />
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4" />
UnhideWhenUsed="false" Name="Dark List Accent 4" />
UnhideWhenUsed="false" Name="Colorful Shading Accent 4" />
UnhideWhenUsed="false" Name="Colorful List Accent 4" />
UnhideWhenUsed="false" Name="Colorful Grid Accent 4" />
UnhideWhenUsed="false" Name="Light Shading Accent 5" />
UnhideWhenUsed="false" Name="Light List Accent 5" />
UnhideWhenUsed="false" Name="Light Grid Accent 5" />
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5" />
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5" />
UnhideWhenUsed="false" Name="Medium List 1 Accent 5" />
UnhideWhenUsed="false" Name="Medium List 2 Accent 5" />
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5" />
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5" />
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5" />
UnhideWhenUsed="false" Name="Dark List Accent 5" />
UnhideWhenUsed="false" Name="Colorful Shading Accent 5" />
UnhideWhenUsed="false" Name="Colorful List Accent 5" />
UnhideWhenUsed="false" Name="Colorful Grid Accent 5" />
UnhideWhenUsed="false" Name="Light Shading Accent 6" />
UnhideWhenUsed="false" Name="Light List Accent 6" />
UnhideWhenUsed="false" Name="Light Grid Accent 6" />
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6" />
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6" />
UnhideWhenUsed="false" Name="Medium List 1 Accent 6" />
UnhideWhenUsed="false" Name="Medium List 2 Accent 6" />
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6" />
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6" />
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6" />
UnhideWhenUsed="false" Name="Dark List Accent 6" />
UnhideWhenUsed="false" Name="Colorful Shading Accent 6" />
UnhideWhenUsed="false" Name="Colorful List Accent 6" />
UnhideWhenUsed="false" Name="Colorful Grid Accent 6" />
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis" />
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis" />
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference" />
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference" />
UnhideWhenUsed="false" QFormat="true" Name="Book Title" />
<![endif]-->
<!--[if gte mso 10]>
<![endif]--> It’s a new year and with that comes renewed hope for those living with ALS. Now is a great opportunity to support The ALS Association Jim “Catfish” Hunter Chapter and fight against Lou Gehrig’s Disease. Listed below are a few suggestions that I believe will help strengthen our partnership together and maintain our progress in 2010.
I know that you are doing everything you can to help create a world without ALS. I hope these suggestions open new doors of possibilities for you. We all share the common goal of a cure for Lou Gehrig’s Disease, and there are many paths to making that goal a reality. Thank you for your unwavering dedication.

Together for a treatment, cure and improved care,
Jerry Dawson
President and CEO <!--[if !supportLineBreakNewLine]-->
<!--[endif]-->
Tue, 01/26/2010 - 2:51pm — mcormican
News Type: General Over the summer, high school senior Macon Cornick’s father was diagnosed with ALS. With help from her mother Gina, she planned a tennis tournament to raise awareness and funds for The ALS Association - Jim "Catfish" Hunter Chapter.
Wed, 01/13/2010 - 12:06pm — mcormican
News Type: General
Ask the Doc: Q & A with Edward Kasarskis, MD, PhD
Edward Kasarskis, MD, PhD is Director of the University of Kentucky ALS Multidisciplinary Clinic at Cardinal Hill Rehabilitation Hospital in Lexington, Kentucky, professor in the Department of Neurology at the University of Kentucky, and Chief of Neurology at the VA Medical Center in Lexington KY.
Q: I heard that the American Academy of Neurology (AAN) has just come out with new guidelines for the care of people with ALS. Will those guidelines change the care I'm getting now or what my doctor is doing for me?
Tue, 01/05/2010 - 8:33am — Anonymous
News Type: General
January, 2010
ALS Association Optimistic New Treatments and Cure
Will Be Found As Organization Commemorates Anniversary
By Gary Wosk, Staff Writer
The ALS Association, marking its 25th anniversary in 2010 as a leader in the fight against ALS, more than ever, is optimistic that major discoveries will be made in the near future that will help people with this disease live longer, better quality lives and that some day there will be a cure.
The Association was created in 1985 when the California-based ALS Society of America merged with the New York-based National ALS Foundation.
Wed, 12/30/2009 - 1:12pm — mcormican
News Type: General Raise money for the Chapter every time you search the web! iSearchiGive.com is a search engine powered by iGive.com,
the internet's first online shopping mall where a portion of each purchase is donated to your favorite cause. iGive is bringing you the best, easiest way to raise money when you search the web.
No hidden fees. No vague percentages. No limits. And donation checks are sent promptly to the Chapter every month.
Mon, 12/21/2009 - 3:28am — Anonymous
News Type: General
December 21, 2009
Senate Appropriates Additional $7.5 Million for ALS Research Program
Includes $2.5 Million for Respite Care
The U.S. Senate has appropriated an additional $7.5 million for the ALS Research Program (ALSRP) at the Department of Defense (DOD), a 50% increase over last year! The funding is in addition to the $6 million (20% increase) Congress appropriated for the National ALS Registry last week and also comes as Congress added another $2.5 million to support the Lifespan Respite Care Act, which helps to fund respite care programs in the states.
Thu, 12/10/2009 - 1:13pm — Anonymous
News Type: General
December 10, 2009
House Votes to Increase ALS Registry Funding
Today the House of Representatives passed legislation that will appropriate an additional $6 million for the National ALS Registry at the Centers for Disease Control and Prevention (CDC). This is a 20% increase over last year and demonstrates that Congress has made funding for the Registry a top priority - something that would not have happened without our Advocates' efforts to contact Congress and tell them why more must be done in the fight against ALS.
Fri, 11/20/2009 - 11:48am — Anonymous
News Type: General
November, 2009
Smoking May Now be Considered an
Established Risk Factor for ALS
While previous studies have indicated a “probable” connection between smoking and ALS, a new study published in the Nov. 17, 2009 issue of Neurology®, the medical journal of the American Academy of Neurology, states that smoking may now be considered an “established” risk factor for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease.
|
|
09/02/2010 - 2:54pm
Don’t put those walking shoes away just yet! We are excited to announce...
08/09/2010 - 4:07pm
I am happy to announce that we recently promoted Angela Murphy to the role...
08/03/2010 - 10:47am
When my grandmother was diagnosed with ALS in August of 2006 I honestly...
06/18/2010 - 9:00am
I wrote the following article for the Asheville Citizen-Times...
06/04/2010 - 8:35am
What a spring season we had with our Walks! Overall, the Walks did...
|